Once vaccines for the COVID-19 virus are approved, the race to market will be hectic. Pharmaceutical companies need to prepare in advance for the upcoming automation requirements of manufacturing and packaging.
Sure. Shippers should be sustainably designed and cost optimized. That often means using the minimum amount of packaging materials. But when it’s crucial for 100% of the products to arrive safely intact, is over-packaging an acceptable given?